BR112021007571A2 - novos usos - Google Patents

novos usos Download PDF

Info

Publication number
BR112021007571A2
BR112021007571A2 BR112021007571-2A BR112021007571A BR112021007571A2 BR 112021007571 A2 BR112021007571 A2 BR 112021007571A2 BR 112021007571 A BR112021007571 A BR 112021007571A BR 112021007571 A2 BR112021007571 A2 BR 112021007571A2
Authority
BR
Brazil
Prior art keywords
fact
alkyl
pde1 inhibitor
methyl
formula
Prior art date
Application number
BR112021007571-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert E. Davis
Kimberly E. Vanover
Original Assignee
Intra-Cellular Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.
Publication of BR112021007571A2 publication Critical patent/BR112021007571A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021007571-2A 2018-10-21 2019-10-21 novos usos BR112021007571A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (1)

Publication Number Publication Date
BR112021007571A2 true BR112021007571A2 (pt) 2021-07-27

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007571-2A BR112021007571A2 (pt) 2018-10-21 2019-10-21 novos usos

Country Status (11)

Country Link
US (2) US12194042B2 (https=)
EP (1) EP3866808A4 (https=)
JP (1) JP7480135B2 (https=)
KR (1) KR20210080418A (https=)
CN (1) CN113194955A (https=)
AU (1) AU2019364274C1 (https=)
BR (1) BR112021007571A2 (https=)
CA (1) CA3117148A1 (https=)
IL (1) IL282396A (https=)
MX (1) MX2021004531A (https=)
WO (1) WO2020086481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210614A1 (en) * 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
MX2023008755A (es) * 2021-01-27 2023-08-02 Intra Cellular Therapies Inc Cristales de sal.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies

Also Published As

Publication number Publication date
US12194042B2 (en) 2025-01-14
CN113194955A (zh) 2021-07-30
US20250090536A1 (en) 2025-03-20
AU2019364274A1 (en) 2021-06-03
EP3866808A4 (en) 2023-04-12
US20210379072A1 (en) 2021-12-09
CA3117148A1 (en) 2020-04-30
AU2019364274C1 (en) 2025-04-10
EP3866808A1 (en) 2021-08-25
IL282396A (en) 2021-06-30
KR20210080418A (ko) 2021-06-30
AU2019364274B2 (en) 2024-10-17
JP7480135B2 (ja) 2024-05-09
JP2022505471A (ja) 2022-01-14
WO2020086481A1 (en) 2020-04-30
MX2021004531A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7579888B2 (ja) 治療用固形製剤
US20250090536A1 (en) Uses
Dubey et al. Suvorexant: The first orexin receptor antagonist to treat insomnia
EP2427193B1 (en) Use of pde7 inhibitors for the treatment of movement disorders
JP6696904B2 (ja) 製剤および医薬組成物
JP7749896B2 (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
US20090275597A1 (en) Methods of treating cns disorders
RU2836384C2 (ru) Новые применения
US20070293505A1 (en) Combination preparations comprising slv308 and a dopamine agonist
HK40057178A (en) Novel uses
KR20090031908A (ko) Slv308 및 l-dopa를 포함하는 병용 제제
US20230355625A1 (en) Methods of treatment
EA041547B1 (ru) Модуляторы рецептора гамма-аминомасляной кислоты типа a против расстройств настроения
Janowsky et al. Cholinergic dysfunction in mood disorders
Novotny et al. Antidepressants and Anticonvulsants/Mood Stabilizers in the Treatment of Autism
HK1167614A (en) Use of pde7 inhibitors for the treatment of movement disorders
HK1167614B (en) Use of pde7 inhibitors for the treatment of movement disorders
BRPI0713695A2 (pt) preparação combinada, uso da mesma, e, composição farmacêutica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]